Naurex built a platform for discovering drugs that enhance synaptic plasticity through a novel mechanism that modulates the NMDA receptor, resulting in drugs that are both highly effective and well-tolerated. The lead candidate, rapastinel (GLYX-13), demonstrated rapid, substantial, and sustained antidepressant activity in Phase 2 studies without psychosis-like side effects.
Cyborg Score Rationale
Naurex successfully developed a validated drug pipeline addressing a major unmet medical need in depression treatment with a differentiated mechanism. The $560M acquisition by a major pharmaceutical company validates the science and market opportunity, though the company is now integrated within a larger entity.
Top Insights
Achieved rare clinical milestone: one of few Chicago-area drug companies to advance a candidate to Phase 3 trials before exit
Proprietary NMDA modulation platform addressed safety liability of competing mechanisms with demonstrated rapid efficacy
Acquired in July 2015 for $560M by Allergan (now AbbVie), validating lead program and de-risking large late-stage development costs
Founded as Northwestern spinout with backing from premier life sciences investors including Adams Street, Baxter Ventures, Lundbeck, and others
Named Competitors
Ketamine and derivatives — Esketamine (Spravato) for treatment-resistant depression
Traditional SSRIs — Sertraline, escitalopram, and other established antidepressants
CNS therapeutics platform — Central nervous system disorder research and development
Recent Developments
(July 2015) Acquired by Allergan plc for $560 million in all-cash transaction
Open the full interactive Naurex Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.